Dominique Charles Valla

Learn More
These recommendations provide a data-supported approach. They are based on the following: (1) formal review and analysis of the recently published world literature on the topic (Medline search); (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines1; (3) guideline policies, including the AASLD Policy on(More)
To survey the burden of liver disease in Europe and its causes 260 epidemiological studies published in the last five years were reviewed. The incidence and prevalence of cirrhosis and primary liver cancer are key to understand the burden of liver disease. They represent the end-stage of liver pathology and thus are indicative of the associated mortality.(More)
BACKGROUND & AIMS Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves renal function, its effect on survival is unknown. This study investigated predictive factors of survival in patients with type 1 HRS treated with(More)
BACKGROUND AND AIMS Splanchnic vein thrombosis is a significant source of complications in candidates for liver transplantation. The aims of this study were: (a) to determine the prevalence of and risk factors for splanchnic vein thrombosis in cirrhotic patients awaiting transplantation and (b) to assess the usefulness of anticoagulation. METHODS A total(More)
BACKGROUND The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. OBJECTIVE To characterize the causes and treatment of incident BCS. DESIGN Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May(More)
Harry L.A. Janssen*, Juan-Carlos Garcia-Pagan, Elwyn Elias, Gilles Mentha, Antoine Hadengue, Dominique-Charles Valla, for the European Group for the Study of Vascular Disorders of the Liver Department of Gastroenterology and Hepatology, University Hospital Rotterdam, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands Hepatic Hemodynamic Laboratory, Liver(More)
Pathophysiology Portal vein obstruction can result from one or several of the following 3 mechanisms: thrombosis, invasion by a malignant tumor (mainly hepatocellular carcinoma) and constriction within a malignant tumor (adenocarcinoma of the pancreas or bile ducts). Compression in the absence of thrombosis, invasion or constriction does not produce portal(More)
UNLABELLED Pegylated interferon alfa-2a (PEG-IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to(More)
BACKGROUND Non-cirrhotic portal hypertension of unknown cause is a poorly understood condition attributed to obstructive portal venopathy. AIM To reassess the manifestations, course, and causes, with special attention to thrombosis. METHODS Analysis of a cohort of 28 patients. RESULTS Gastrointestinal bleeding occurred in 11 patients. Liver failure(More)
UNLABELLED Current recommendations for early anticoagulation in acute portal vein thrombosis unrelated to cirrhosis or malignancy are based on limited evidence. The aim of this study was to prospectively assess the risk factors, outcome, and prognosis in patients managed according to these recommendations. We enrolled 102 patients with acute thrombosis of(More)